| abstract |
A compound of the formula (1) is described which includes pharmaceutically acceptable salts thereof, wherein: R 1 is aryl or heteroaryl optionally substituted with R 8; R2 is H or alkyl or CH2 (forming the part of a ring with R3, R4 or R5); R3 is H, alkyl, CH2OH or CH2OR6 and can be part of a ring with R2; R4 is H, alkyl CH2OH or CH2OR6 and can be part of a ring with R2; R5 is H, alkyl. CH2OH or CH2OR6 and can be the part of a ring with R2; R6 is H, alkyl, COH, COOR9, CON (R9) 2, COR9, COR10, COR11, P (O) nR9, P (O) nR10S (O) nR10 or S (O) nR9 and may be part of a ring with R2, R3, R4 or R5; R7 is H. alkyl, COOR9, COOR11, COR9 or CON (R9) 2, and may be part of a ring with R2, R3, R4, R5 or R6; R8 is alkyl, CF3, OR9, OCOR9, CONH2, CN, F, Cl, Br, I, N (R9) 2, R9 is H, alkyl or cycloalkyl; R10 is aryl or heteroaryl (optionally substituted with R8) or a four to seven member ring (which is optionally substituted with R8 and may contain one or more additional heteroatoms selected from the list O, S (O) n and NR9); R11 is alkyl optionally substituted with R8 or R10; and n is 0, 1 or 2; provided that when R3, R4 or R5 are CH2OH then R6 is not H, and that when R7 is H and R3, R4 and R5 are alkyl then R6 is not H, said compound has therapeutic use in the treatment against an associated condition with the proliferation of T lymphocytes or that is regulated by pro and / or anti-inflammatory cytokines. |